Kornimate/medical-research-clean huggingface dataset:
additional effects of quranic listening meditation in combination with high intensity interval training in obese adults

Conditions: Obesity

Summary: to determine the additional effects of quranic listening meditation, in combination with high-intensity interval training on cardiovascular fitness and mental health in obese adults.


Eligibility criteria:
inclusion criteria: * obese adults (bmi ≥ 30) * age range: 18-45 years * no previous experience with quranic listening meditation since last 4 weeks. * no contraindications for engaging in high-intensity physical activity * able to attend regular sessions at clinic and follow the study protocol. * willingness to undergo pre and post-assessments for cardiovascular fitness and mental health measures. exclusion criteria: * individuals with a history of the medical condition being studied * those who are currently taking medication that may affect the study * participants with a history of mental health disorders * individuals who are pregnant or breastfeeding * those who have previously participated in a similar study * participants with a history of substance abuse or addiction
transcutaneous auricular vagus nerve stimulation treatment on functional dyspepsia

Conditions: Functional Dyspepsia

Summary: objective: to observe the effect of the treatment of transcutaneous auricular vagus nerve stimulation (tavns) for the functional dyspepsia (fd). methods: we accrued 94 patients at beijing tongren hospital. all treatments were self-administered by the patients at home after training at the hospital. patients completed questionnaires at baseline and after 4 weeks, 8 weeks, 12 weeks. the fd symptoms index, functional dyspepsia quality of life scale (fddql), hamilton anxiety scale (hama), hamilton depression scale (hamd), and self-depression rating scale (sds) were performed to evaluate the therapeutic effects. a difference of p \< 0.05 was considered statistically significant.


Eligibility criteria:
inclusion criteria: * 1. age \>=18 and age \<=65. 2. clinical diagnosis of functional dyspepsia. exclusion criteria: * 1. history of depression, tumors, thyroid disease, diabetes, cardiac diseases. 2. history of gastrointestinal surgery. 3. pregnant or lactating women.

Keywords: transcutaneous auricular vagus nerve stimulation
an investigation into bone micro-architecture in women with type 2 diabetes

Conditions: Type 2 Diabetes Mellitus

Summary: the number of people with type 2 diabetes is growing. this puts a lot of pressure on the health care systems. type 2 diabetes is often associated with health problems, like poor eyesight, muscle coordination, muscle strength, and blood flow. poor bone health may also be a concern for people with type 2 diabetes. a large proportion of people with type 2 diabetes will break a bone in their lifetime. the risk of this happening in older people with type 2 diabetes is greater than the risk in older people without diabetes. fracturing a bone can be very painful, and lead to serious consequences, especially if the individual experiences a hip fracture. the elevated fracture risk, seen in those with type 2 diabetes, is puzzling because people with type 2 diabetes often appear to have normal, healthy bones compared to people of the same age without diabetes. bone micro-structure, which is not assessed by traditional bone densitometry systems (ie: dxa) contributes to overall bone strength. the hypothesis of this study is that bone micro-structure is of poorer quality (reduced trabecular thickness, increased trabecular spacing) in postmenopausal women with type 2 diabetes, compared to age-matched control participants.


Eligibility criteria:
inclusion criteria: * female * \>= 65 years old * postmenopausal for \> 5 years (who definition of menopause) exclusion criteria: * currently taking osteoporosis related medication (hrt, serm, bisphosphonate, pth, calcitonin, fluoride) * had cancer in past 10 years, likely to metastasize to bone (ie: breast, lung) * have intrinsic bone disease (ie: paget's disease, cushings syndrome) * have untreated malabsorption syndrome (ie: celiac disease) * renal insufficiency (crcl \<30ml/min) * hyperparathyroidism, hypoparathyroidism * chronic systemic glucocorticosteroid use \> 3mos, dose\>2.5mg daily

Keywords: type 2 diabetes mellitus osteoporosis bone quality magnetic resonance imaging fracture postmenopausal women >65 years old
treatment study for ischemic optic neuropathy with opthalmic timolol maleate 0.5%

Conditions: Optic Neuropathy, Ischemic; Anterior Ischemic Optic Neuropathy; Ischemic Optic Neuropathy; Optic Neuropathy, Anterior Ischemic

Summary: the purpose of this study is to evaluate the feasibility of rapid evaluation and administration of ophthalmic timolol maleate in the treatment of non-arteritic anterior ischemic optic neuropathy. secondary goals are to evaluate if such treatment reduces the progression or improves recovery of patients who are randomly assigned to treatment versus standard of care.

non-arteritic anterior ischemic optic neuropathy (naion) currently has no widely accepted acute treatment to improve recovery or prevent progression in the first month. it causes monocular vision loss with potential second eye involvement in 15% at 5 years. this leads to significant disability. it is the most common acute optic neuropathy in patients over 55 years of age. the final mechanism of injury is believed to be ischemic. increasing perfusion of the optic nerve may reduce damage and prevent progression. reduction in intraocular pressure has been shown to increase optic disc perfusion in animal models. timolol maleate is a widely used medication for glaucoma that reduces intraocular pressure. treatment with timolol maleate may improve optic disc perfusion in naion and reduce ischemic damage from this condition. this study aims to enroll and treat patients with timolol maleate 0.5% within 48 hours of symptom onset to assess feasibility of the study design and potential benefit of rapid intraocular pressure reduction.

Eligibility criteria:
inclusion criteria: * age \>40 * sudden, painless monocular vision loss with edema of the optic disc * clinical diagnosis is non-arteritic anterior ischemic optic neuropathy * relative afferent pupil defect (rapd) at first study visit exclusion criteria: * onset of vision loss \>48 hours from time of enrollment * history of asthma or copd * history of heart block or sinus bradycardia * allergy to any beta blocker * history of multiple sclerosis or optic neuropathy * active ocular inflammation on examination * currently being treated for cancer or systemic vasculitis * history of glaucoma or use of medications that lower iop * symptomatic cataract, retinopathy, macular disease or amblyopia in the symptomatic eye * iop of \<10 at baseline * ocular surgery in past three months * women who are pregnant, breast-feeding or may become pregnant * inability to provide informed consent or follow up at three months * currently enrolled in any other study drug trial or previously enrolled in this study

Keywords: ischemic optic neuropathy non-arteritic anterior ischemic optic neuropathy naion ischemic optic neuropathy intraocular pressure
ideas, concerns, expectations. implementing patient-centered communication

Conditions: Communication; Back Pain

Summary: exploring patients' ideas, concerns and expectation (ice) is a communication tool to promote patient centredness and shared decision making during a consultation. this study evaluates whether offering ice training to doctors can decrease overdiagnosis in the management of acute backache.

the study is a cluster randomized trial recruiting general practitioner from practices in northern bavaria/germany forming a research network within the recently implemented framework of pro pricare (preventing overdiagnosis in primary care). at baseline, the intervention group (24 out of 48 doctors) will take part in a one-day training session covering theoretical background and clinical implementation of ice communication in association with frequent consultation contents. primary outcome measure are referrals to physiotherapists and medical specialists such as orthopaedic surgeons, neurologists and radiologists, obtained from routinely collected practice data. secondary outcomes are patients' and doctors' satisfaction measured via structured questionnaires and semi-structured interviews. blinding is attempted by hiding the trial purpose and treatment allocation from the participating doctors.

Eligibility criteria:
inclusion criteria: * aged 18 * first time seeing doctor because of the defined high frequent consultation issue referring on recommendation of the national guideline exclusion criteria: * not first time seeing the doctor during the recommended time of the national guideline

Keywords: patient-centered-communication primary care over investigation communication consultation shared-decision making medical education low back pain
determination of cetuximab versus cisplatin early and late toxicity events in hpv+ opscc

Conditions: Oropharyngeal Squamous Cell Carcinoma

Summary: oropharyngeal squamous cell carcinoma (opscc) incidence is increasing rapidly in the developed world. this has been attributed to a rise in human papillomavirus (hpv) infection. hpv+opscc is considered a distinct disease entity, affecting younger patients and has a good prognosis following treatment. subsequently, patients can live with the considerable side effects for several decades. radiotherapy and cetuximab (epidermal growth factor receptor-inhibitor) have demonstrated similar efficacy to 'platin' chemoradiotherapy (current standard treatment containing platinum-based compounds) in head and neck cancer, but is potentially less toxic. results of this trial will be used to determine the optimum treatment of this debilitating cancer, with the primary aim of decreasing toxicity and improving quality of life for hpv+opscc patients.


Eligibility criteria:
inclusion criteria: * american joint committee on cancer (ajcc) tnm stage iii-iva (t3n0-t4n0, and t1n1-t4n3) oropharyngeal squamous cell carcinoma (scc) tumours * clinical multidisciplinary team decision to treat with primary curative cisplatin chemoradiotherapy * no previous treatment including surgery, except node biopsies or diagnostic tonsillectomy * medically fit (ecog 0, 1 or 2) * adequate cardiovascular, haematological, renal and hepatic function * age \> 18 years * written informed consent given * using adequate contraception \[male and female participants\]. must take contraceptive measures during, and for at least six months after treatment. exclusion criteria: * distant metastasis (i.e. ajcc tnm stage ivc disease) * ajcc tnm stage t1-2n0 disease * treated with primary radical surgery to the primary site (e.g. resection) * concurrent use of cyp3a4 inducers or inhibitors. \[a standard course of dexamethasone or aprepitant for the prevention of cisplatin-induced nausea and vomiting is permitted\] * serious cardiac illness or other medical conditions precluding the use of cisplatin or cetuximab \[no history of clinically significant cardiac disease, serious arrhythmias, or significant conduction abnormalities; no uncontrolled seizure disorder; no active neurologic disease; no neuropathy greater than grade 1\] * patients who have p16+ tumours who also have n2b, n2c or n3 nodal disease and whose lifetime smoking history is also more than 10 pack years (i.e. have both risk factors). * pregnant or lactating * previous treatment for any other cancer with cytotoxics, radiotherapy or anti-egfr therapies * inadequate renal, haematological or liver functions \[absolute neutrophil count \ 1.5 times upper limit of normal (uln); alkaline phosphatase \> 2.5 times uln; ast and alt \> 2.5 times uln. creatinine \> 1.5 mg/dl; creatinine clearance \< 60 ml/min\] * patients with clinically significant hearing impairment * life expectancy less than 3 months * other malignancy within the past 3 years except basal cell skin cancer or pre-invasive carcinoma of the cervix.
the effects of oral dipyridamole treatment on the innate immune response during human endotoxemia

Conditions: Endotoxemia

Summary: during sepsis and septic shock the immune response can be overwhelming leading to excessive tissue damage, organ failure and death. ideally, the inflammatory response is modulated leading to both adequate protection to invading pathogens as well as limitation of an exuberant immune response. in the last few years adenosine is proposed to have a central role in the modulation of inflammation. in unfavorable conditions such as hypoxia, ischemia or inflammation adenosine is quickly up-regulated; with concentrations up to tenfold in septic patients. many animal studies have shown that adenosine is able to attenuate the inflammatory response and decrease mortality rates. therefore, pharmacological elevation of the adenosine concentration is an potential target to attenuate inflammation and limit organ injury. dipyridamole, an adenosine re-uptake inhibitor is able to increase the adenosine concentration and limit ischemia-reperfusion injury. in order to study the effects of dipyridamole on the inflammatory response we aim to use the so called human endotoxemia model. this model permits elucidation of key players in the immune response to a gram negative stimulus in vivo, therefore serving as a useful tool to investigate potential novel therapeutic strategies in a standardized setting.


Eligibility criteria:
inclusion criteria: * age ≥ 18 and ≤ 35 years * male * healthy exclusion criteria: * use of any medication. * history of allergic reaction to dipyridamole * bleeding disorder. * smoking. * previous spontaneous vagal collapse. * history, signs or symptoms of cardiovascular disease. * cardiac conduction abnormalities on the ecg consisting of a 2nd degree atrioventricular block or a complex bundle branch block. * hypertension (defined as rr systolic \> 160 or rr diastolic \> 90). * hypotension (defined as rr systolic \< 100 or rr diastolic \< 50). * renal impairment (defined as plasma creatinin \>120 μmol/l). * liver enzyme abnormalities or positive hepatitis serology. * positive hiv serology or any other obvious disease associated with immune deficiency. * febrile illness in the week before the lps challenge. * participation in another drug trial or donation of blood 3 months prior to the planned lps challenge.

Keywords: adenosine endotoxin innate immunity dipyridamole
is the preoperative preparation of sickle cell patients optimal: assessment of practices and post-operative complications

Conditions: Sickle Cell Disease

Summary: children with sickle cell disease systematically receive a transfusion 2 to 5 days before scheduled surgery (with the exception of minor surgeries) in order to avoid post-operative complications of which the vaso-occlusive crisis and acute thoracic syndrome are the most frequent. this standardized preoperative protocol was established on the basis of the results of large-scale randomized studies, most of which date back over ten years, and which have demonstrated the beneficial effects of transfusion (or transfusion exchange) preoperatively. to date, several other more recent studies (but not controlled) have questioned this type of systematic management. the purpose of this study is to review retrospectively data of sickle cell children who have undergone elective surgery at the huderf in the last ten years and to identify the eventual complications encountered. the most common procedures in these patients are: tonsillectomy with or without associated adenoids, splenectomy and cholecystectomy. general data on sickle cell disease (history, genotype, g6pd deficiency, biology and previous complications), pre-surgical preparation, surgery and post surgical management and complications will be collected and analyzed. this retrospective analysis will allow an objective assessment of the current quality of care and will provide useful data to improve patient management.


Eligibility criteria:
inclusion criteria: * sickle cell disease with surgery during the 2010-2019 period exclusion criteria: * none
target gcat registry

Conditions: Giant Cell Arteritis

Summary: a longitudinal post-marketing surveillance registry nested within the uk gca consortium that assesses the effectiveness and safety of tocilizumab in controlling refractory or relapsing forms of gca in patients who require escalation of therapy to reach sustained remission. half the patients recruited will have been prescribed tocilizumab (cases) and the other half will be prescribed alternative therapies (controls). there are four study visits over 18 months: baseline, 6 months, 12 months and 18 months. at each visit data is collected on demographics; diagnosis and investigations; previous and concomitant medications; medical history; co-morbidities, vital signs; smoking and alcohol; disease activity and damage; routine laboratory tests; reason for starting escalation therapy. safety data is collected on an ongoing basis.


Eligibility criteria:
inclusion criteria: * patient must have a diagnosis of gca and be eligible for the uk gca consortium study * willing and able to consent * have refractory or relapsing gca as defined by the nhs england commissioning statement for tocilizumab. * require treatment escalation

Keywords: tocilizumab giant cell arteritis
a study on precutting methods of endoscopic submucosal dissection for gastric neoplasms located at lesser curvature side of antrum

Conditions: Gastric Adenoma and Early Gastric Cancer

Summary: endoscopic submucosal dissection (esd) is an advanced technique that enables en bloc resection of superficial tumors in the gastrointestinal tract. esd, however, is a time-consuming procedure that requires a high level of endoscopic skill to achieve a desirable oncologic outcome. especially, esd for the lesion which is located in the antrum of lesser curvature side is difficult. because the antrum of lesser curvature side is dependent position, irrigated water and blood may prevent visual field of esd. generally, whole precutting around the lesion during the esd is performed prior to dissection. however, it is expected that partial precutting method for the lesion located in the antrum of the lesser curvature may improve the visibility of esd because it can help us the flap of the lesion evaginated easily. therefore, we aimed to evaluate the procedure time of esd for the lesion located in the antrum of the lesser curvature according to the precutting methods (whole precutting vs. partial precutting).


Eligibility criteria:
inclusion criteria: 1. over 19 years old 2. patients with gastric adenoma or early gastric cancer exclusion criteria: 1. patients who has undergone subtotal gastrectomy 2. patients who has undergone gastrostomy 3. patients with local recurred gastric adenoma or early gastric cancer
cardiovascular reserve evaluation in survivors of transplant, crest study

Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Hematopoietic and Lymphoid Cell Neoplasm; Hodgkin Lymphoma; Myelodysplastic Syndrome; Non-Hodgkin Lymphoma; Plasma Cell Myeloma

Summary: this study evaluates how well the heart, lungs, and muscles are working individually, and how these systems are working together in transplant survivors. information collected in this study may help doctors to understand why hematopoietic stem cell transplant survivors are at higher risk for developing cardiovascular disease.

primary objectives: i. evaluate cardiovascular reserve capacity, as measured by peak oxygen consumption (vo2peak), in hematopoietic cell transplantation (hct) survivors. ii. define the determinants of vo2peak impairment in hct survivors. outline: patients undergo echocardiogram to assess cardiac function and mechanics, cardiopulmonary exercise test, pulmonary function test, musculoskeletal ultrasound, bioelectrical impedance analysis to measure total lean body mass and percent body fat), physical function tests, and collection of blood samples within 45 days from the start of conditioning therapy, and at 6 months, 1 year, and 2 years post-transplant.

Eligibility criteria:
inclusion criteria: * age at hct \>= 18 years * diagnosis of acute leukemia (myeloid, lymphoid), lymphoma (non-hodgkin, hodgkin), multiple myeloma or myelodysplastic syndromes * planning to undergo first autologous or allogeneic transplant * able to fluently read and write in english * able to understand and sign the study specific informed consent form (icf) * physically able and willing to complete all study procedures exclusion criteria: * unstable bone lesions per electronic medical record review and/or notification from patient's primary physician * unstable angina or history of acute myocardial infarction (\< 5 days of any planned study procedures) * recurrent syncope * acute myocarditis or pericarditis * symptomatic severe aortic stenosis * uncontrolled arrhythmia causing symptoms * pulmonary embolus \< 3 month of study procedures * thrombosis of lower extremities * moderate or severe persistent asthma (national asthma education \& prevention) * room air desaturation at rest =\< 85% * non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (i.e. infection, renal failure, thyrotoxicosis) * anemia (hemoglobin \[hgb\] \< 8 g/dl)
avandamet bioequivalence study brazil - fed administration

Conditions: Diabetes Mellitus, Type 2

Summary: the study is prospective, open-label, randomized, crossover, with 02 treatments, 02 sequences, and 02 periods. the volunteers received, in each period, the reference or the test formulation after standardized meals.

this is an open-label, randomized, crossover study with 02 treatments, 02 sequences, and 02 periods, in which the healthy volunteers received, in each period, the test or the reference formulation after standardized meals. test product is rosiglitazone maleate + metformin - avandamet 4 mg + 1000 mg (glaxosmithkline brasil ltda) in the form of film coated tablets. reference product is rosiglitazone maleate + metformin - avandamet 2 mg + 500 mg (glaxo smith kline brasil ltda) in the form of film coated tablets. the population is composed by 26 healthy volunteers, adults, of both genders and their ages varied between 18 and 50 years. their body mass index (bmi) varied between 18,5 and 25. there are no restrictions regarding the ethnic group. the relative bioavailability of the two formulations, after oral administration, will be evaluated based on statistical comparisons of relevant pharmacokinetic parameters obtained from data of drug concentration in blood.

Eligibility criteria:
exclusion criteria: * the volunteer has a known hypersensitivity to the study drug or to compounds chemically related; * history or presence of hepatic or gastrointestinal illnesses, or other condition that interferes over the drug's absorption, distribution, excretion or metabolism; * history of neurological, endocrine, pulmonary, hamatologic, immune, brain, metabolic or cardiovascular illness; * hypo or hypertension of any etiologic that needs pharmacologic treatment; * the results of the laboratory exams are out of the values considered as normal according this protocol's rules, unless that they are considered as clinically irrelevant by the investigator; * has history of alcohol or drugs abuse; * history of use drug inducing and/or inhibitors of hepatic metabolism within 30 days prior to drug study administration; * use of mao inhibitors two weeks before the start of treatment; - use of inhibitors of 5-th reuptake, * pregnancy or breastfeeding, * smoking; * use of regular medication within 4 weeks prior to study iniciation; * use of experimental drug or participation in any clinical study within 6 months prior to study iniciation. inclusion criteria: * age between 18 and 50 years; * body mass index ≥ 18,5 and ≤25,0, can vary up to 15% for the upper limit (18,5 to 28,75); * good health conditions; * obtain the informed consent's signed.

Keywords: metformin rosiglitazone healthy volunteers avandamet fed conditions bioequivalence